Bayer to spend up to $4bn on Asklepios BioPharmaceutical
27-10-2020
Intercept sues Apotex over Ocaliva generic
26-08-2020
Senior counsel at Bayer highlights pharmaceutical TM challenges
15-03-2019
EPO revokes Bayer broccoli patent
09-11-2018
photobyphm / Shutterstock.com
Bayer Healthcare Pharmaceuticals has settled a patent infringement suit with generics manufacturer Apotex, after claiming that its version of a cancer treatment infringed two patents for cancer drug Stivarga (regorafenib).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Bayer, Apotex, settle, suit, cancer, drug, patent, infringement, Stivarga, generics, regorafenib, Pharmaceuticals, settled
